Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

• Status: Completed
• Trial end date: 2012-09-10
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia A or B

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Body weight between 50 and 100 kg, both inclusive

• Body mass index (BMI) between 18.0 kg/m2 and 25.0 kg/m2, both inclusive

• For haemophilia subjects only: Diagnosed with severe haemophilia A or B

Exclusion Criteria:

• Known or suspected hypersensitivity to trial product(s) or related products

• Surgery planned to occur during the trial

• Any major and/or orthopaedic surgery within 30 days prior to trial product administration